• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Lu Chen, MD, PhD; Syed Huq, MD; Humphrey Gardner, MD; Antonin R. de Fougerolles, PhD; Stefano Barabino, MD; M. Reza Dana, MD, MSc, MPH

Arch Ophthalmol. 2007;125(6):783-788.

Objective  To investigate the role of very late antigen 1 (VLA-1) (also known as integrin receptor ₁β₁) in corneal transplantation inflammation and allograft survival.

Methods  Cell infiltration and vasculogenesis (both angiogenesis and lymphangiogenesis) associated with allodisparate corneal transplantation were assessed in VLA-1–deficient conditions and controls by immunofluorescent microscopic studies. Corneal allograft survival was also assessed after anti–VLA-1 antibody treatment and in VLA-1 knockout recipient mice.

Results  Anti–VLA-1 antibody treatment leads to a profound reduction in the granulocytic, monocytic, and T-cell infiltration after corneal transplantation. In addition, corneal angiogenesis and lymphangiogenesis were both significantly suppressed in VLA-1 knockout mice. Remarkably, universal graft survival was observed in both anti–VLA-1 antibody treatment and knockout mice.

Conclusions  Very late antigen 1 blockade markedly reduces inflammation and inflammation-induced tissue responses, including vasculogenic responses, associated with corneal transplantation and promotes allograft survival.

Clinical Relevance  These studies offer insights into important integrin-mediated mechanisms of corneal transplant–related inflammation and provide possible new integrin-based immunotherapies for transplant rejection.

Author Affiliations: Laboratory of Immunology, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Mass (Drs Chen, Huq, Barabino, and Dana); Research Pathology, Biogen Idec (Drs Gardner and de Fougerolles), Cambridge, Mass.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combined Blockade of VEGFR-3 and VLA-1 Markedly Promotes High-Risk Corneal Transplant Survival
Zhang et al.
IOVS 2011;52:6529-6535.
ABSTRACT | FULL TEXT  

Very Late Antigen-1 Mediates Corneal Lymphangiogenesis
Grimaldo et al.
IOVS 2011;52:4808-4812.
ABSTRACT | FULL TEXT  

Combined Blockade of VEGFR-2 and VEGFR-3 Inhibits Inflammatory Lymphangiogenesis in Early and Middle Stages
Yuen et al.
IOVS 2011;52:2593-2597.
ABSTRACT | FULL TEXT  

Spontaneous Lymphatic Vessel Formation and Regression in the Murine Cornea
Zhang et al.
IOVS 2011;52:334-338.
ABSTRACT | FULL TEXT  

Novel Discovery of LYVE-1 Expression in the Hyaloid Vascular System
Zhang et al.
IOVS 2010;51:6157-6161.
ABSTRACT | FULL TEXT  

Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin
Cueni et al.
Blood 2010;116:4376-4384.
ABSTRACT | FULL TEXT  

Differential Distribution of Blood and Lymphatic Vessels in the Murine Cornea
Ecoiffier et al.
IOVS 2010;51:2436-2440.
ABSTRACT | FULL TEXT  

Bevacizumab Application Delays Epithelial Healing in Rabbit Cornea
Kim et al.
IOVS 2009;50:4653-4659.
ABSTRACT | FULL TEXT